Vilaprisan

Drug Profile

Vilaprisan

Alternative Names: BAY 1002670; S-PRAnt; S-PRM; sPRM

Latest Information Update: 20 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Infertility therapies; Small molecules; Sulfones
  • Mechanism of Action Progesterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Uterine leiomyoma
  • Phase II Endometriosis

Most Recent Events

  • 10 Jul 2017 Bayer plans to initiate a phase I drug-drug interaction trial in Healthy volunteers in USA (NCT03210246)
  • 30 Jun 2017 Phase-III clinical trials in Uterine leiomyoma in USA (PO) (NCT03194646)
  • 23 May 2017 Bayer initiates enrolment in the phase III ASTEROID 6 trial for Uterine leiomyoma in Finland (PO) (EudraCT2016-004822-41)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top